Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3695 - Relationship between Symptoms and Health-Related Quality of Life Benefits in Patients with Carcinoid Syndrome: Post-Hoc Analyses from TELESTAR

Date

10 Sep 2017

Session

Poster display session

Presenters

Marianne Pavel

Citation

Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368

Authors

M. Pavel1, D. Cella2, J.L. Beaumont2, S. Hudgens3, F. Marteau4, M. Feuilly4, S. Gabriel4, A. Houchard4, J. Ramage5, D. Hörsch6, M.H. Kulke7

Author affiliations

  • 1 Gastroenterology And Hepatology, Endocrinology & Metabolic Diseases, Charité University Medicine Berlin, 13353 - Berlin/DE
  • 2 Feinberg School Of Medicine, Northwestern University, Chicago/US
  • 3 Clinical Outcomes, Clinical Outcomes Solutions, Tuscon/US
  • 4 Health Economics & Outcomes Research, Ipsen, 92100 - Boulogne-Billancourt/FR
  • 5 Gastroenterology Department, Hampshire Hospitals, Basingstoke/GB
  • 6 Department Of Internal Medicine, Zentralklinik Bad Berka, Bad Berka/DE
  • 7 Gastrointestinal Cancer Treatment Center, Dana-Farber Cancer Institute, Boston/US
More

Resources

Abstract 3695

Background

The safety and efficacy of telotristat ethyl (TE) in patients (pts) with metastatic neuroendocrine tumors (NETs) and carcinoid syndrome (CS) not adequately controlled with somatostatin analogs (SSAs) have been demonstrated. TE-treated pts showed significantly greater reductions in bowel movement (BM) frequency and more presented with durable response than placebo (PBO)-treated pts. These post-hoc analyses examined the relationship between improvements in symptoms and health-related quality of life (HRQoL) in pts who were durable responders (DRs; n = 48) and non-durable responders (NDRs; n = 87), irrespective of treatment group, in TELESTAR (NCT01677910).

Methods

Pts were randomized 1:1:1 to TE 250mg, 500mg, and PBO three times daily during the 12-week (wk) double-blind (DB) treatment period; durable response was predefined as a daily BM frequency reduction of ≥ 30% from baseline for ≥50% of the DB period. Clinical symptoms were assessed via daily records, HRQoL by the EORTC QLQ-C30 and QLQ-GINET21 questionnaires. The difference in arithmetic means and associated 95% CIs were used as a descriptive measure of group effects.

Results

135 pts were randomized, 45 in each group. The mean difference [95% CI] in change from baseline between DRs and NDRs at Wk12 was (1.8 [-2.3, -1.2]) for daily BM frequency, (-1.2 [-1.6, -0.7]) for daily flushing, (-38.7 [-70.0, -7.3] mg/24 hrs) for u5-HIAA levels, (-1.2 [-1.8, -0.6]) for abdominal pain severity and (-0.3 [-0.4, -0.2]) for urgency to defecate. DRs showed meaningful and/or significant improvements in QLQ-C30 global health (8.1 [-0.3, 16.5]), summary score (4.9 [0.6, 9.2]), social functioning (5.1 [-4.7, 14.9]), nausea/vomiting (-7.5 [-15.4, 0.4]), pain (-16.0 [-27.0, -5.0]), dyspnea (-5.7 [-15.5, 4.1]), diarrhea (-14.7 [-26.5, -2.9]), and GINET21 gastrointestinal symptoms (-9.3 [-16.3, -2.2]) versus NDRs.

Conclusions

Durable response was associated with reductions in the symptoms and overall clinical burden of CS. DRs showed significant and/or meaningful improvements in global HRQoL, nausea, pain, diarrhea, and gastrointestinal symptoms.

Clinical trial identification

NCT01677910

Legal entity responsible for the study

Lexicon Pharmaceuticals

Funding

Lexicon Pharmaceuticals and Ipsen

Disclosure

M. Pavel: Consulting fees and honoaria from Ipsen, Lexicon Pharmaceuticals, Novartis, Pfizer. D. Cella: Consulting fees and research grants from Bayer, BMS, Ipsen, Novartis, Pfizer. J.L. Beaumont: Consulting fees from Novartis. F. Marteau, M. Feuilly, S. Gabriel, A. Houchard: Employee of Ipsen. J. Ramage: Speaker’s fees from Ipsen, Novartis, Pfizer; Research grants from IEL, Ipsen, Novartis, Pfizer. D. Hörsch: Consulting and/or honoraria and/or advisory boards from Ipsen, Lexicon Pharmaceuticals, Novartis, Pfizer; Research grants from Ipsen, Novartis, Pfizer. M.H. Kulke: Consulting fees from Ipsen, Lexicon Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.